Angiotensin II Receptor Blockers (ARBs) Market Emerging Trends and Company Profiles to Watch- Daichii Sankyo, Lupin, Novartis, Abbvie, Takeda in 2018-2026
ARB drugs are found to have least number of side effects in patients / users, which in turn increases its demand and hence is more preferred than other hypertension drugs. ARBs are gaining popularity as they have the capability of improving the quality of life of the patients. Unlike ACEIs (Angiotensin converting enzyme inhibitors), ARMs do not cause cough or danger of swelling of the lips, throat, or tongue. Moreover, growth in patient population is augmenting the market for ARBs...
View full press release